ArticleOral oncology2024

Letter to the editor "A phase 1 study of concurrent cabozantinib and cetuXimab in recurrent or metastatic head and neck squamous cell cancer".

Silambarasan Tamil SelvanPubMed ↗Publisher ↗

No numbers read from the abstract.